Subscribe
Models
Our Products
Featured Catalog
Humanized Mouse Models
Tool Mice
Custom Model Services
Preclinical Solutions
Resources
About Us
huMPZL2-Q74* Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
huMPZL2-Q74* Mouse
Product Name
huMPZL2-Q74* Mouse
Product ID
C002132
Strain Name
C57BL/6Cya-Mpzl2tm1(hMPZL2*Q74X)/Cya
Background
C57BL/6Cya
Status
When using this mouse strain in a publication, please cite “huMPZL2-Q74* Mouse (Catalog C002132) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
Basic Information
Related Resource
Basic Information
Gene Name
MPZL2
Gene Alias
EVA, EVA1, DFNB111
NCBI ID
Chromosome
Chr 11 (Human)
MGI ID
Datasheet
Strain Description
Myelin protein zero-like 2 (MPZL2), also known as epithelial V-like antigen 1 (EVA1), is a single-pass type I transmembrane glycoprotein of the immunoglobulin superfamily that contains an Ig-like V-type domain in its extracellular region and mediates homophilic cell-cell adhesion [1]. MPZL2 is widely expressed; among fetal tissues the highest expression is found in the inner ear, whereas among adult tissues the highest levels are found in the thymus and lung [2]. Biallelic loss of MPZL2 function causes autosomal recessive non-syndromic deafness (DFNB111), in which patients present with early-onset, progressive sensorineural hearing loss without vestibular involvement [2-3]. Among DFNB111 patients of East Asian ancestry, most carry the c.220C>T (p.Q74*) variant, which is considered a founder mutation in East Asian populations [4-5]. MPZL2 has been regarded as a potential therapeutic target for DFNB111, and the relevant interventions remain at the preclinical stage, including adeno-associated virus (AAV)-mediated human MPZL2 gene supplementation and base editing to correct the c.220C>T mutation [5-6].
The huMPZL2-Q74* mouse is a humanized model in which the sequence from upstream of the mouse Mpzl2 start codon to downstream of the 3'UTR was replaced with the corresponding sequence of the human MPZL2 gene, and the p.Q74* (CAG to TAG) mutation was introduced into exon 2 of the human MPZL2 gene. This model can be used for studying the pathogenesis of DFNB111, as well as for screening, development, and preclinical in vivo evaluation of MPZL2-targeted therapies.
Reference
Güttinger M, Sutti F, Panigada M, et al. Epithelial V-like antigen (EVA), a novel member of the immunoglobulin superfamily, expressed in embryonic epithelia with a potential role as homotypic adhesion molecule in thymus histogenesis. J Cell Biol. 1998;141(4):1061-1071. doi:10.1083/jcb.141.4.1061
Wesdorp M, Murillo-Cuesta S, Peters T, et al. MPZL2, encoding the epithelial junctional protein myelin protein zero-like 2, is essential for hearing in man and mouse. Am J Hum Genet. 2018;103(1):74-88. doi:10.1016/j.ajhg.2018.05.011
Bademci G, Abad C, Incesulu A, et al. MPZL2 is a novel gene associated with autosomal recessive nonsyndromic moderate hearing loss. Hum Genet. 2018;137(6-7):479-486. doi:10.1007/s00439-018-1901-4
Li W, Guo L, Chen B, Shu Y, Li H. MPZL2 variant analysis with whole exome sequencing in a cohort of Chinese hearing loss patients. Int J Pediatr Otorhinolaryngol. 2023;171:111635. doi:10.1016/j.ijporl.2023.111635
Hu SW, Jeong S, Jiang L, et al. PAM-flexible adenine base editing rescues hearing loss in a humanized MPZL2 mouse model harboring an East Asian founder mutation. Nat Commun. 2025;16:7186. doi:10.1038/s41467-025-62562-8
Jang SH, Song HG, Joo SY, et al. Gene supplementation with precise transgene expression rescues hearing loss in a mouse model with an Mpzl2 East Asian founder variant. Mol Ther. 2026;34(1):216-231. doi:10.1016/j.ymthe.2025.10.005
Strain Strategy
The sequence from upstream of the mouse Mpzl2 start codon to downstream of the 3'UTR was replaced with the corresponding sequence of the human MPZL2 gene, and the p.Q74* (CAG to TAG) mutation was introduced into exon 2 of the human MPZL2 gene.

Figure 1. Gene editing strategy of huMPZL2-Q74* mice.
Application Area
Pathogenesis studies of DFNB111 and other hereditary hearing loss;
Research and development, screening, and preclinical in vivo evaluation of MPZL2-targeted therapies and gene therapy strategies.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
